7Baggers
 Cassava Sciences (NASDAQ:SAVA) Upgraded to Hold at Wall Street Zen  MarketBeat Sun, 16 Nov 2025 08:21:29 GMT
 cassava sciences faces critical juncture amid strategic pivot  AD HOC NEWS Fri, 14 Nov 2025 06:20:05 GMT
 Cassava Sciences files $200M mixed securities shelf  MSN Thu, 13 Nov 2025 22:38:34 GMT
 doj dismisses indictment against cassava advisor amid legal flaws  Compliance Week Thu, 13 Nov 2025 20:37:30 GMT
 Cassava Sciences to offer securities up to $200 million  MarketScreener Thu, 13 Nov 2025 11:19:21 GMT
 Cassava Sciences Outperforms Expectations With Smaller Q3 Loss  Finimize Wed, 12 Nov 2025 14:58:58 GMT
 Cassava Sciences reports Q3 EPS (22c) vs (58c) last year  TipRanks Wed, 12 Nov 2025 13:50:04 GMT
 Cassava Sciences Q3 net loss narrows, beats expectations  MarketScreener Wed, 12 Nov 2025 13:11:48 GMT
 cassava sciences shares: is the downturn bottoming out?  AD HOC NEWS Tue, 11 Nov 2025 06:07:04 GMT
 Cassava Sciences (NASDAQ:SAVA) Trading Down 3% - What's Next?  MarketBeat Fri, 07 Nov 2025 08:20:28 GMT
 published on: 2025-11-05 21:11:47  fcp.pa.gov.br Thu, 06 Nov 2025 00:11:47 GMT
 cassava sciences shares extend losses amid bearish sentiment  AD HOC NEWS Wed, 05 Nov 2025 15:42:04 GMT

Cassava Sciences, Inc
(NASDAQ:SAVA) 

SAVA stock logo

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-b...

Founded: 1998
Full Time Employees: 9
CEO: Remi Barbier  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends